**Article references for *How do people with MS respond to COVID-19 vaccines?***

* Achiron et al [Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies](https://journals.sagepub.com/doi/full/10.1177/17562864211012835) Apr-21
* Apostolidis et al – preprint [Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy](https://www.medrxiv.org/content/10.1101/2021.06.23.21259389v1.full-text) Jun-21
* Bigaut et al [Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti?SARS-CoV-2 Antibodies](https://nn.neurology.org/content/8/5/e1055) Jul-21
* Capuano et al [Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab](https://journals.sagepub.com/doi/full/10.1177/17562864211038111) Aug-21
* Cabreira et al [Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations](https://www.mdpi.com/2076-393X/9/7/773) Jul-21
* Drulovic et al [Humoral response to sars-cov-2 and covid-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies](https://www.msard-journal.com/article/S2211-0348%2821%2900417-X/fulltext) Jul-21
* Filippo et al [mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis](https://pubmed.ncbi.nlm.nih.gov/34408003/) Aug-21
* Gadani et al - preprint [Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy](https://www.medrxiv.org/content/10.1101/2021.08.23.21262472v1) Aug-21
* Giovannoni et al [COVID-19 vaccines and multiple sclerosis disease-modifying therapies](https://linkinghub.elsevier.com/retrieve/pii/S2211034821004223) Jul-21
* Guerreri et al [Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience](https://link.springer.com/article/10.1007/s00415-021-10663-x) Jun-21
* Huang et al [Willingness to receive a COVID-19 vaccine in people with multiple sclerosis - UK MS Register survey](https://www.msard-journal.com/article/S2211-0348%2821%2900442-9/fulltext) Jul-21
* Kakara [Humoral and cell-based responses following SARS-CoV-2 mRNA vaccination of patients with multiple sclerosis on B-cell depleting therapy](https://ectrims2021.abstractserver.com/program/#/details/presentations/1172) Oct-21 [upcoming presentation at ECTRIMS 2021 13-15 October.]
* Lotan et al [Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel](https://pubmed.ncbi.nlm.nih.gov/34288285/) Jul-21
* Louapre et al [Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders](https://jnnp.bmj.com/content/early/2021/08/01/jnnp-2021-326904) Aug-21
* Madelon et al [Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines](https://www.medrxiv.org/content/10.1101/2021.07.21.21260928v1.full-text) Jul-21
* Moor et al – preprint [Humoral and cellular responses to mRNA vaccines against SARS-CoV2 in patients with a history of CD20-B-cell depleting therapy](https://www.medrxiv.org/content/10.1101/2021.07.04.21259848v2) Jul-21
* Rommer et al [SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?](https://journals.sagepub.com/doi/abs/10.1177/13524585211039128)
* Shulz et al - preprint [Association of Naïve B Cells with Humoral Response to SARS-CoV-2 Vaccination](https://www.medrxiv.org/content/10.1101/2021.08.11.21261898v1.full-text)
* Sormani et al [SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study](https://journals.sagepub.com/doi/10.1177/13524585211035318) Jul-21
* Tallantyre et al - preprint [COVID-19 vaccine response in people with multiple sclerosis](https://www.medrxiv.org/content/10.1101/2021.07.31.21261326v1.full-text)